{"id":5523,"date":"2026-10-25T16:48:22","date_gmt":"2026-10-25T20:48:22","guid":{"rendered":"https:\/\/canasanta.ca\/?p=5523"},"modified":"2026-10-25T16:48:22","modified_gmt":"2026-10-25T20:48:22","slug":"divarasib-reduce-riesgo-muerte-cancer-pulmon","status":"publish","type":"post","link":"https:\/\/canasanta.ca\/en\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/","title":{"rendered":"UN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N"},"content":{"rendered":"

Un medicamento experimental de Roche ha conseguido una mejora significativa de supervivencia en una forma concreta de c\u00e1ncer de pulm\u00f3n. Divarasib redujo en un 44% el riesgo de muerte frente a dos tratamientos ya aprobados en un ensayo cl\u00ednico fase III cuyos resultados completos fueron presentados este domingo en el Congreso de la Sociedad Europea de Oncolog\u00eda M\u00e9dica (ESMO) en Madrid.<\/p>\n

El estudio Krascendo 1 incluy\u00f3 a 338 pacientes con c\u00e1ncer de pulm\u00f3n de c\u00e9lulas no peque\u00f1as avanzado o metast\u00e1sico y una mutaci\u00f3n KRAS G12C que ya hab\u00edan recibido tratamiento. Los resultados fueron publicados simult\u00e1neamente en The New England Journal of Medicine, seg\u00fan inform\u00f3 Roche.<\/p>\n

 <\/p>\n

SEIS MESES M\u00c1S DE SUPERVIVENCIA<\/strong><\/h3>\n

Los pacientes tratados con divarasib alcanzaron una supervivencia global mediana de 17,7 meses, frente a 12 meses entre quienes recibieron sotorasib o adagrasib, dos inhibidores de primera generaci\u00f3n utilizados actualmente contra esta mutaci\u00f3n. En t\u00e9rminos estad\u00edsticos, el nuevo f\u00e1rmaco redujo el riesgo de muerte en un 44%.<\/p>\n

La diferencia tambi\u00e9n apareci\u00f3 al medir cu\u00e1nto tiempo permanecieron los pacientes sin que la enfermedad avanzara. La supervivencia libre de progresi\u00f3n fue de 9,8 meses con divarasib, comparada con 5,7 meses en el grupo de control, una reducci\u00f3n del 42% en el riesgo de progresi\u00f3n o muerte.<\/p>\n

 <\/p>\n

UNA MUTACI\u00d3N DIF\u00cdCIL DE ATACAR<\/strong><\/h3>\n

KRAS G12C es una alteraci\u00f3n gen\u00e9tica presente en una parte de los c\u00e1nceres de pulm\u00f3n de c\u00e9lulas no peque\u00f1as. Durante a\u00f1os, KRAS fue considerado un objetivo especialmente dif\u00edcil para los medicamentos, hasta que una nueva generaci\u00f3n de terapias dirigidas consigui\u00f3 bloquear determinadas variantes de la prote\u00edna.<\/p>\n

Divarasib pertenece a esa nueva generaci\u00f3n de inhibidores. El ensayo lo compar\u00f3 directamente con sotorasib y adagrasib, algo relevante porque no se trata simplemente de medir el medicamento frente a placebo, sino frente a terapias que ya forman parte de las opciones disponibles para estos pacientes.<\/p>\n

 <\/p>\n

CASI EL DOBLE DE RESPUESTAS<\/strong><\/h3>\n

La tasa de respuesta objetiva \u2014la proporci\u00f3n de pacientes cuyos tumores disminuyeron de tama\u00f1o de manera significativa\u2014 alcanz\u00f3 el 58% con divarasib, frente al 32% con los tratamientos de comparaci\u00f3n. La duraci\u00f3n mediana de esa respuesta fue de 11,9 meses, comparada con 6,9 meses en el grupo de control.<\/p>\n

Roche inform\u00f3 que no aparecieron nuevas se\u00f1ales de seguridad y que los efectos adversos relacionados con el tratamiento fueron en su mayor\u00eda de grado bajo y manejables. Un 4,8% de los pacientes suspendi\u00f3 divarasib por efectos adversos relacionados con el medicamento, frente a un 11,7% en el grupo de comparaci\u00f3n.<\/p>\n

 <\/p>\n

A\u00daN NO ES UN TRATAMIENTO APROBADO<\/strong><\/h3>\n

Los resultados son importantes, pero divarasib contin\u00faa siendo un medicamento en investigaci\u00f3n. La compa\u00f1\u00eda dijo que trabaja con las autoridades sanitarias para intentar llevar el tratamiento a los pacientes, por lo que todav\u00eda deber\u00e1 superar los procesos regulatorios correspondientes antes de convertirse en una opci\u00f3n de uso general.<\/p>\n

El dato central del estudio es dif\u00edcil de ignorar: frente a dos medicamentos ya aprobados para la misma alteraci\u00f3n gen\u00e9tica, divarasib consigui\u00f3 prolongar la supervivencia mediana cerca de seis meses. Si las autoridades reguladoras confirman el balance entre beneficio y seguridad, el ensayo podr\u00eda modificar el tratamiento de este subtipo de c\u00e1ncer de pulm\u00f3n.<\/p>","protected":false},"excerpt":{"rendered":"

Divarasib redujo un 44% el riesgo de muerte frente a tratamientos actuales en un ensayo fase III de c\u00e1ncer de pulm\u00f3n con mutaci\u00f3n KRAS G12C.<\/p>","protected":false},"author":284226809,"featured_media":5524,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_wpcom_ai_launchpad_first_post":false,"_jetpack_hide_featured_image":false,"_jetpack_featured_image_duplicate_dismissed":0,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[33205457,2127],"tags":[33206790,33207179,33207180,33206304],"class_list":["post-5523","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-al-dia","category-salud","tag-cancer-de-pulmon","tag-divarasib","tag-kras-g12c","tag-roche"],"acf":{"introduccion":"","fuentes_y_referencias":"

Fuentes<\/strong><\/h3> Reuters \u2014 \u2018Roche says divarasib cut risk of death 44% in lung cancer trial\u2019, 25 de octubre de 2026. Roche \u2014 \u2018Roche\u2019s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer\u2019, 25 de octubre de 2026. The New England Journal of Medicine \u2014 resultados del estudio fase III Krascendo 1, publicados el 25 de octubre de 2026.","autor":748},"yoast_head":"\nUN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N - Ca\u00f1asanta<\/title>\n<meta name=\"description\" content=\"Divarasib redujo un 44% el riesgo de muerte frente a tratamientos actuales en un ensayo fase III de c\u00e1ncer de pulm\u00f3n con mutaci\u00f3n KRAS G12C.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/canasanta.ca\/en\/health\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"UN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N\" \/>\n<meta property=\"og:description\" content=\"Divarasib redujo un 44% el riesgo de muerte frente a tratamientos actuales en un ensayo fase III de c\u00e1ncer de pulm\u00f3n con mutaci\u00f3n KRAS G12C.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/canasanta.ca\/en\/health\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/\" \/>\n<meta property=\"og:site_name\" content=\"Ca\u00f1asanta\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-25T20:48:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?resize=1200,630&quality=85&strip=all&ssl=1\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Ca\u00f1asanta\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ca\u00f1asanta\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/\"},\"author\":{\"name\":\"Ca\u00f1asanta\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\"},\"headline\":\"UN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N\",\"datePublished\":\"2026-10-25T20:48:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/\"},\"wordCount\":575,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?fit=1200%2C899&quality=82&strip=all&ssl=1\",\"keywords\":[\"c\u00e1ncer de pulm\u00f3n\",\"divarasib\",\"KRAS G12C\",\"Roche\"],\"articleSection\":[\"AL D\u00cdA!\",\"Salud\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/\",\"name\":\"UN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N - Ca\u00f1asanta\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?fit=1200%2C899&quality=82&strip=all&ssl=1\",\"datePublished\":\"2026-10-25T20:48:22+00:00\",\"description\":\"Divarasib redujo un 44% el riesgo de muerte frente a tratamientos actuales en un ensayo fase III de c\u00e1ncer de pulm\u00f3n con mutaci\u00f3n KRAS G12C.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/#primaryimage\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?fit=1200%2C899&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?fit=1200%2C899&quality=82&strip=all&ssl=1\",\"width\":1200,\"height\":899,\"caption\":\"Paciente someti\u00e9ndose a una tomograf\u00eda computarizada de pulm\u00f3n\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/salud\\\/divarasib-reduce-riesgo-muerte-cancer-pulmon\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AL D\u00cdA!\",\"item\":\"https:\\\/\\\/canasanta.ca\\\/category\\\/al-dia\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"UN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#website\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"name\":\"Ca\u00f1asanta\",\"description\":\"Magazine\",\"publisher\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/canasanta.ca\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#organization\",\"name\":\"Ca\u00f1asanta\",\"url\":\"https:\\\/\\\/canasanta.ca\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"contentUrl\":\"https:\\\/\\\/i0.wp.com\\\/canasanta.ca\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1\",\"width\":1500,\"height\":500,\"caption\":\"Ca\u00f1asanta\"},\"image\":{\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/canasanta.ca\\\/#\\\/schema\\\/person\\\/21421a3c6f1733be6c5c590190fd8e93\",\"name\":\"Ca\u00f1asanta\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g\",\"caption\":\"Ca\u00f1asanta\"},\"sameAs\":[\"http:\\\/\\\/canasantaonline-pbuqn.wordpress.com\"],\"url\":\"https:\\\/\\\/canasanta.ca\\\/en\\\/author\\\/canasantaonline\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"UN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N - Ca\u00f1asanta","description":"Divarasib redujo un 44% el riesgo de muerte frente a tratamientos actuales en un ensayo fase III de c\u00e1ncer de pulm\u00f3n con mutaci\u00f3n KRAS G12C.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/canasanta.ca\/en\/health\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/","og_locale":"en_US","og_type":"article","og_title":"UN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N","og_description":"Divarasib redujo un 44% el riesgo de muerte frente a tratamientos actuales en un ensayo fase III de c\u00e1ncer de pulm\u00f3n con mutaci\u00f3n KRAS G12C.","og_url":"https:\/\/canasanta.ca\/en\/health\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/","og_site_name":"Ca\u00f1asanta","article_published_time":"2026-10-25T20:48:22+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?resize=1200,630&quality=85&strip=all&ssl=1","type":"image\/jpeg"}],"author":"Ca\u00f1asanta","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ca\u00f1asanta","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/#article","isPartOf":{"@id":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/"},"author":{"name":"Ca\u00f1asanta","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93"},"headline":"UN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N","datePublished":"2026-10-25T20:48:22+00:00","mainEntityOfPage":{"@id":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/"},"wordCount":575,"commentCount":0,"publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"image":{"@id":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?fit=1200%2C899&quality=82&strip=all&ssl=1","keywords":["c\u00e1ncer de pulm\u00f3n","divarasib","KRAS G12C","Roche"],"articleSection":["AL D\u00cdA!","Salud"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/","url":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/","name":"UN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N - Ca\u00f1asanta","isPartOf":{"@id":"https:\/\/canasanta.ca\/#website"},"primaryImageOfPage":{"@id":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/#primaryimage"},"image":{"@id":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/#primaryimage"},"thumbnailUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?fit=1200%2C899&quality=82&strip=all&ssl=1","datePublished":"2026-10-25T20:48:22+00:00","description":"Divarasib redujo un 44% el riesgo de muerte frente a tratamientos actuales en un ensayo fase III de c\u00e1ncer de pulm\u00f3n con mutaci\u00f3n KRAS G12C.","breadcrumb":{"@id":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/#primaryimage","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?fit=1200%2C899&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?fit=1200%2C899&quality=82&strip=all&ssl=1","width":1200,"height":899,"caption":"Paciente someti\u00e9ndose a una tomograf\u00eda computarizada de pulm\u00f3n"},{"@type":"BreadcrumbList","@id":"https:\/\/canasanta.ca\/salud\/divarasib-reduce-riesgo-muerte-cancer-pulmon\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/canasanta.ca\/"},{"@type":"ListItem","position":2,"name":"AL D\u00cdA!","item":"https:\/\/canasanta.ca\/category\/al-dia\/"},{"@type":"ListItem","position":3,"name":"UN F\u00c1RMACO REDUCE 44% EL RIESGO DE MUERTE EN C\u00c1NCER DE PULM\u00d3N"}]},{"@type":"WebSite","@id":"https:\/\/canasanta.ca\/#website","url":"https:\/\/canasanta.ca\/","name":"Ca\u00f1asanta","description":"Magazine","publisher":{"@id":"https:\/\/canasanta.ca\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/canasanta.ca\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/canasanta.ca\/#organization","name":"Ca\u00f1asanta","url":"https:\/\/canasanta.ca\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/","url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","contentUrl":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/LOGO_CS.jpg?fit=1500%2C500&quality=82&strip=all&ssl=1","width":1500,"height":500,"caption":"Ca\u00f1asanta"},"image":{"@id":"https:\/\/canasanta.ca\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/canasanta.ca\/#\/schema\/person\/21421a3c6f1733be6c5c590190fd8e93","name":"Ca\u00f1asanta","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/925594ac8e278f26e2e7403182642a1af3a9d1885cb6168deb61adb801ffd2b3?s=96&d=identicon&r=g","caption":"Ca\u00f1asanta"},"sameAs":["http:\/\/canasantaonline-pbuqn.wordpress.com"],"url":"https:\/\/canasanta.ca\/en\/author\/canasantaonline\/"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_shortlink":"https:\/\/wp.me\/phoxY0-1r5","jetpack-related-posts":[{"id":4353,"url":"https:\/\/canasanta.ca\/en\/salud\/roche-dice-que-su-nuevo-farmaco-supera-al-estandar-en-cancer-de-pulmon-kras-g12c\/","url_meta":{"origin":5523,"position":0},"title":"Roche dice que su nuevo f\u00e1rmaco supera al est\u00e1ndar en c\u00e1ncer de pulm\u00f3n KRAS G12C","author":"Ca\u00f1asanta","date":"October 19, 2026","format":false,"excerpt":"Roche anunci\u00f3 resultados de fase 3 en los que divarasib super\u00f3 a los inhibidores KRAS G12C de primera generaci\u00f3n en c\u00e1ncer de pulm\u00f3n avanzado previamente tratado.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Microscopio en laboratorio de investigaci\u00f3n oncol\u00f3gica","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-oncologica-KRAS-G12C-%E2%80%94-portada-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-oncologica-KRAS-G12C-%E2%80%94-portada-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-oncologica-KRAS-G12C-%E2%80%94-portada-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-oncologica-KRAS-G12C-%E2%80%94-portada-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-oncologica-KRAS-G12C-%E2%80%94-portada-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5179,"url":"https:\/\/canasanta.ca\/en\/salud\/nuevo-farmaco-frena-59-avance-cancer-mama\/","url_meta":{"origin":5523,"position":1},"title":"NUEVO F\u00c1RMACO FRENA UN 59% EL AVANCE DEL C\u00c1NCER DE MAMA","author":"Ca\u00f1asanta","date":"October 23, 2026","format":false,"excerpt":"Un tratamiento experimental redujo un 59% el riesgo de progresi\u00f3n o muerte en una forma com\u00fan de c\u00e1ncer de mama avanzado frente a la quimioterapia.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Investigadora observa cultivos celulares en un laboratorio oncol\u00f3gico","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-cancer-de-mama-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-cancer-de-mama-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-cancer-de-mama-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-cancer-de-mama-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Investigacion-cancer-de-mama-1200x630-1.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5165,"url":"https:\/\/canasanta.ca\/en\/salud\/vacuna-arnm-reduce-42-riesgo-recaida-melanoma\/","url_meta":{"origin":5523,"position":2},"title":"UNA VACUNA DE ARNm REDUCE UN 42% EL RIESGO DE RECA\u00cdDA DEL MELANOMA","author":"Ca\u00f1asanta","date":"October 23, 2026","format":false,"excerpt":"Una vacuna personalizada de ARNm de Moderna y Merck, combinada con Keytruda, redujo un 42% el riesgo de reca\u00edda o muerte por melanoma en un ensayo de fase 3.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Investigaci\u00f3n de una vacuna personalizada contra el c\u00e1ncer en laboratorio","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Vacuna-personalizada-de-ARNm-contra-el-melanoma.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":5580,"url":"https:\/\/canasanta.ca\/en\/salud\/nuevo-farmaco-alarga-vida-cancer-endometrio\/","url_meta":{"origin":5523,"position":3},"title":"UN NUEVO F\u00c1RMACO ALARGA LA VIDA EN C\u00c1NCER DE ENDOMETRIO","author":"Ca\u00f1asanta","date":"October 26, 2026","format":false,"excerpt":"Un f\u00e1rmaco experimental de Merck prolong\u00f3 la supervivencia en c\u00e1ncer de endometrio avanzado y recibi\u00f3 revisi\u00f3n prioritaria de la FDA.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Secci\u00f3n patol\u00f3gica de un \u00fatero con adenocarcinoma del endometrio","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Adenocarcinoma-del-endometrio-%E2%80%94-imagen-patologica.jpg?fit=1200%2C431&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Adenocarcinoma-del-endometrio-%E2%80%94-imagen-patologica.jpg?fit=1200%2C431&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Adenocarcinoma-del-endometrio-%E2%80%94-imagen-patologica.jpg?fit=1200%2C431&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Adenocarcinoma-del-endometrio-%E2%80%94-imagen-patologica.jpg?fit=1200%2C431&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Adenocarcinoma-del-endometrio-%E2%80%94-imagen-patologica.jpg?fit=1200%2C431&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":2238,"url":"https:\/\/canasanta.ca\/en\/al-dia\/el-papa-leon-xiv-tiene-cancer-de-pulmon-le-extirpan-parte-del-organo\/","url_meta":{"origin":5523,"position":4},"title":"POPE LEO XIV HAS LUNG CANCER: PART OF HIS LUNG IS REMOVED","author":"Ca\u00f1asanta","date":"October 13, 2026","format":false,"excerpt":"El Vaticano confirm\u00f3 este martes que el papa Le\u00f3n XIV, de 71 a\u00f1os, padece c\u00e1ncer de pulm\u00f3n. El diagn\u00f3stico lleg\u00f3 despu\u00e9s de una intervenci\u00f3n quir\u00fargica en Roma durante la cual los m\u00e9dicos le extirparon el l\u00f3bulo inferior del pulm\u00f3n derecho. La noticia supone el problema de salud m\u00e1s serio conocido\u2026","rel":"","context":"In "Actualidad"","block_context":{"text":"Actualidad","link":"https:\/\/canasanta.ca\/en\/category\/politica\/actualidad\/"},"img":{"alt_text":"CS Papal Portrait","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/CS_Papal-Portrait_001.jpg?fit=1200%2C629&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/CS_Papal-Portrait_001.jpg?fit=1200%2C629&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/CS_Papal-Portrait_001.jpg?fit=1200%2C629&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/CS_Papal-Portrait_001.jpg?fit=1200%2C629&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/CS_Papal-Portrait_001.jpg?fit=1200%2C629&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]},{"id":7245,"url":"https:\/\/canasanta.ca\/en\/ciencia\/vasos-sanguineos-resistencia-vegfr2-angiogenesis\/","url_meta":{"origin":5523,"position":5},"title":"BLOOD VESSELS DEFY A RULE OF CANCER","author":"Ca\u00f1asanta","date":"November 7, 2026","format":false,"excerpt":"Un estudio de Nature descubre c\u00f3mo algunas c\u00e9lulas forman vasos sangu\u00edneos sin el receptor VEGFR2 y aporta pistas sobre la resistencia a tratamientos contra el c\u00e1ncer.","rel":"","context":"In "AL D\u00cdA!"","block_context":{"text":"AL D\u00cdA!","link":"https:\/\/canasanta.ca\/en\/category\/al-dia\/"},"img":{"alt_text":"Imagen m\u00e9dica abstracta roja y azul para ilustrar la formaci\u00f3n de vasos sangu\u00edneos","src":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Vascularizacion-y-resistencia-a-terapias-imagen-de-contexto.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Vascularizacion-y-resistencia-a-terapias-imagen-de-contexto.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=350%2C200 1x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Vascularizacion-y-resistencia-a-terapias-imagen-de-contexto.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=525%2C300 1.5x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Vascularizacion-y-resistencia-a-terapias-imagen-de-contexto.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=700%2C400 2x, https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/11\/Vascularizacion-y-resistencia-a-terapias-imagen-de-contexto.jpg?fit=1200%2C630&quality=82&strip=all&ssl=1&resize=1050%2C600 3x"},"classes":[]}],"jetpack_featured_media_url":"https:\/\/i0.wp.com\/canasanta.ca\/wp-content\/uploads\/2026\/10\/Tomografia-pulmonar-%E2%80%94-cancer-de-pulmon.jpg?fit=1200%2C899&quality=82&strip=all&ssl=1","_links":{"self":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/5523","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/users\/284226809"}],"replies":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/comments?post=5523"}],"version-history":[{"count":1,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/5523\/revisions"}],"predecessor-version":[{"id":5525,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/posts\/5523\/revisions\/5525"}],"acf:post":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/autor\/748"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media\/5524"}],"wp:attachment":[{"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/media?parent=5523"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/categories?post=5523"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/canasanta.ca\/en\/wp-json\/wp\/v2\/tags?post=5523"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}